Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q3 FY2023 Earnings Presentation
31 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, February 2023
Slide 1: Q3FY23 Investor Presentation
IOL Chemicals And Pharmaceuticals Limited Q3FY23 Investor Presentation February 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by IOL Chemicals & Pharmaceuticals Limited (the “Companies”, IOL) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on i
Slide 3: Table of Contents
Table of Contents 01 IOLCP at a glance 02 Financial Highlights 03 Company Overview Quarterly Income Statement Milestones About IOL Chemicals and Pharmaceuticals Ltd. Half yearly Income statement Core management team Quarterly performance highlights Annual Income Statement Board of Directors Segmenta
Slide 4: About IOL Chemicals and Pharmaceuticals Limited
About IOL Chemicals and Pharmaceuticals Limited Incorporated in 1986, IOLCP is one of the leading Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Team size of 2300+ employees Credit Rating: A+, outlook; stable (Care Ratings Limited)
Slide 5: Executive Director & CEO Message
Executive Director & CEO Message Dr. Sanjay Chaturvedi, Executive Director & CEO Businesses across the world had a tough ride in year 2022 as persistent high inflation, geopolitical conflict, volatility in commodity prices and tightened monetary policy by most central banks put pressure on growth tr
Slide 6: Quarterly performance highlights
Quarterly performance highlights Operational Highlights Q3FY23 Financial Performance ▪ EDQM Authority issued CEP Certificate for 530.12 49.68 9.37% Levetiracetam. Revenues EBITDA EBITDA Margin ▪ EDQM certification to supply Pantoprazole Sodium Sesquihydrate API across European 24.15 4.56% market PAT
Slide 7: Segmental highlights
Segmental highlights Chemical Segment Pharmaceutical Segment Operating Revenue net intersegment (Rs. crore) Operating Revenue (Rs. crore) 350 310 303 303 300 297 300 276 279 300 238 290 285 250 218 280 200 270 150 260 258 100 250 50 240 230 0 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q3FY22 Q4FY22 Q1FY23 Q
Slide 8: Geographical & segmental break-up
Geographical & segmental break-up Geographical Break-up (Rs. crore) Segmental Revenue (Rs. crore) 2000 25% 36% 38% 34% 31% 1222 1172 1179 1638 1121 1600 26% 1008 1355 891 1250 1199 799 1200 735 1038 679 624 556 800 633 647 645 613 546 354 431 400 350 0 FY18 FY19 FY20 FY21 FY22 9MFY23 FY18 FY19 FY20
Slide 9: Financial Overview
FINANCIAL OVERVIEW
Slide 10: Quarterly Income Statement
Quarterly Income Statement Particulars (Rs. Cr) Q3 FY23 Q3 FY22 YoY Q2 FY23 QoQ Revenues 523.5 555.1 -5.7% 541.4 -3.3% Other Income 6.6 8.9 5.1 Total Income 530.1 564.0 -6.0% 546.5 -3.0% Total Expenses 480.4 495.9 509.8 EBITDA 49.7 68.1 -27.0% 36.7 35.4% EBITDA Margin (%) 9.4% 12.1% -270 bps 6.7% 27
Slide 11: 9 Monthly Income Statement
9 Monthly Income Statement Particulars (Rs. Cr) 9M FY23 9M FY22 YoY Revenues 1,629.9 1,611.5 1.1% Other Income 16.9 25.1 Total Income 1,646.8 1,636.6 Total Expenses 1,499.2 1,398.3 EBITDA 147.6 213.2 -38.1% EBITDA Margin (%) 9.0% 13.2% -560 bps Depreciation 34.0 32.3 Finance Cost 11.6 6.0 Profit Bef
Slide 12: Income statement
Income statement Particulars (Rs. Cr) FY18 FY19 FY20 FY21 FY22 9M FY23 Revenues 983.3 1,685.3 1,894.5 1,967.0 2,184.0 1,629.9 Other Income 6.3 10.4 16.0 24.3 32.0 16.9 Total Income 989.6 1,695.7 1,910.5 1,991.3 2,216.0 1,646.8 Total Expenses 863.7 1,275.7 1,320.6 1,375.2 1,927.6 1,499.2 EBITDA 125.9
Slide 13: Balance Sheet
Balance Sheet Balance Sheet (Rs. Cr) FY18 FY19 FY20 FY21 FY22 H1-FY23 Shareholders' Funds 215.7 474.3 813.5 1260.4 1390.3 1440.0 Debt 421.9 284.0 56.0 0.0 0.0 0.0 Other Long Term Liabilities 33.6 20.8 79.7 59.1 56.6 56.6 Other Current Liabilities 180.9 162.8 220.6 290.6 513.4 512.4 Equity & Liabilit
Slide 14: 5-years Performance
5-years Performance Operational Revenue (Rs Cr) EBITDA (Rs Cr) and EBITDA Margin (%) PAT (Rs Cr) and PAT Margin (%) 30.9% 30.9% 22.3% 19.0% 24.8% 13.0% 14.0% 12.7% 8.9% 7.5% 4.5% 2.8% 990 1,696 1,911 1,991 2,216 1,647 126 420 590 616 288 147 28 237 361 445 166 75 FY18 FY19 FY20 FY21 FY22 9M-FY23 FY1
Slide 15: Product wise Segmentation
Product wise Segmentation FY18 FY22 9MFY23 362, 37% 1181, 54% 739, 45% 35, 3% 355, 22% 351, 16% 586, 60% 652, 30% 536, 33% Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's Amount in Rs. crore 15
Slide 16: Company Overview
COMPANY OVERVIEW
Slide 17: Milestones
Milestones ▪ 2009 - Commencement of ▪ 2019 - Unit-06 for ▪ 1996 - Commencement IBB, MCA and Acetyl Chloride ▪ 2015 - USFDA, EIR for Pantoprazole ▪ Commenced of Ethyl Acetate Plant Plants Ibuprofen (Dedicated) commercial ▪ 1999 - Commencement ▪ 2010 - Listing on NSE Co- ▪ 2016 - Unit-03 for ▪ 2020 -
Slide 18: Core management team
Core management team Varinder Gupta (Managing Director) ▪ Wide and rich experience of more than 35 years Vikas Gupta in the chemical & fertilizer industry and along (Executive Director) with a comprehensive approach and strong ▪ Academically equipped with knowledge and possesses Pharma API industry
Slide 19: Board of Directors
Board of Directors Rajender Mohan Malla (Chairman and Independent Director) ▪ With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs Harpal Singh ▪ In his most recent executive roles, he was MD & (Independent Director) CEO of PTC I
Slide 20: Certifications and Accreditations
Certifications and Accreditations Approved USFDA facility since EUGMP Certification in 2013, Certificate of Suitability from Certified Halal in accordance 2015, recertified in 2019 2017 & Recertification in 2020 Certificate of DMF Registration EDQM with Shariah Board Guidelines From MFDS Korea Certi
Slide 21: Business Overview
= bu > oc Lu => O n n Lu Zz WY _) co
Slide 22: Business segment – Pharmaceuticals
Business segment – Pharmaceuticals IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen • Among the largest producer of Metformin in India Product application across var
Slide 23: Business segment – Specialty chemicals
Business segment – Specialty chemicals IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 tonnes p.a. Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 1,00,000 tonnes p.a. • India’s
Slide 24: Manufacturing facilities
Balance Manufacturing facilities API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC 1 3 5 intermediates & Specialty chemicals in Dedicated blocks involved in system, PSA Nitrogen & Purified water continuous product delivery manner manufacturing of APIs along with 127 MTPH
Slide 25: Core sustainability pillars
Core sustainability pillars Environment Social Governance ▪ Strive to minimize the adverse impact ▪ Construction and renovation of schools ▪ Implemented a sound and well- on environment, health and Safety by and provided technical equipment for structured corporate governance that upgrading technolo
Slide 26: Industry Overview
INDUSTRY OVERVIEW
Slide 27: Industry overview – Pharmaceuticals
Industry overview – Pharmaceuticals Indian Pharmaceutical Export Market-API World Pharmaceutical Industry • Pharmaceutical exports from India registered a growth of 4.22 per cent to reach USD 14.57 billion during the April- October period. India’s pharma exports are likely to touch an all-time high
Slide 28: Industry overview – Specialty Chemicals
Industry overview – Specialty Chemicals • India’s chemical sector is witnessing transformative shift, driven by the availability of low-cost labor as well as a global phenomenon of China plus one strategy that attempts to focus on development of alternative supply-chain market for the sector apart f
Slide 29: Way Forward
WAY FORWARD i
Slide 30: Way forward
Way forward Four pronged strategy for growth Focus on Capacity Improved Expanding Regulated expansion in asset Non-Ibuprofen Pharma & utilization Markets Business Chemicals Focus on efficiently utilizing Plan to enhance our product Target non- Ibuprofen business Capacity expansion for existing asset
Slide 31: Thank You
Thank You Company : Investor Relations Advisors : IOL Chemicals & Adfactorspr Pvt. Ltd. Pharmaceuticals Ltd. Mr. Pardeep Kumar Khanna, Snighter Albuquerque CFO snighter.a@adfactorspr.com pardeepkhanna@iolcp.com Darshan Mankad darshan.mankad@adfactorspr.com www.iolcp.com www.adfactorspr.com
IOL Chemicals and Pharmaceuticals — Q3 FY2023 Earnings Presentation on 6ix